When we think about innovation in oncology, our attention naturally turns to new drugs, new targets, and breakthrough discoveries. Yet many of the greatest improvements in patient care have come from a different source: making existing therapies work better.
Across oncology, researchers are improving outcomes not only by replacing established treatments, but by optimizing how they are delivered, dosed, combined, sequenced, and applied. The result is often greater precision, lower toxicity, and better clinical outcomes — built on biology we already understand.
Across oncology, this shift is driving meaningful advances in a wide range of treatment approaches, from radiation and chemotherapy to surgery and endocrine therapy.
Delivering Radiation More Precisely
Radiation therapy has been a cornerstone of cancer treatment for decades. Its effectiveness stems from its ability to damage the DNA of cancer cells, preventing them from dividing and ultimately causing them to die, while aiming to preserve as much healthy tissue as possible. Today’s radiopharmaceuticals are refining, not replacing, that approach by delivering radiation directly to tumor cells through highly specific biological targets.
Unlike conventional external beam radiotherapy, which delivers radiation from outside the body to a defined treatment area, radiopharmaceuticals are administered systemically and circulate through the bloodstream. They consist of a radioactive isotope linked to a targeting molecule that selectively binds to proteins expressed on cancer cells, delivering radiation directly to the tumor while limiting exposure to surrounding healthy tissue.
Approved therapies such as lutetium Lu 177 dotatate (Lutathera) for gastroenteropancreatic neuroendocrine tumors and lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for metastatic castration-resistant prostate cancer demonstrate how greater precision can improve outcomes while limiting damage to healthy tissue. Pivotal trials have shown that lutetium Lu 177 dotatate and lutetium Lu 177 vipivotide tetraxetan improve clinically meaningful outcomes with manageable safety profiles, supporting their role as precise radiopharmaceutical therapies in neuroendocrine tumors and metastatic castration-resistant prostate cancer.[3] The field is also advancing through theranostics, where the same target is used for both imaging and treatment, helping physicians identify patients most likely to benefit before therapy begins.
The principle is simple: the radiation is familiar. The way it is delivered is changing. [1][2]
Optimizing Chemotherapy
Chemotherapy has long relied on the principle of administering the maximum tolerated dose (MTD) to maximize tumor cell killing, followed by treatment-free intervals that allow healthy tissues to recover.
Metronomic chemotherapy takes a different approach. Instead of high doses administered intermittently, it delivers low doses more frequently and continuously, often using oral regimens that enable continuous treatment to maintain therapeutic pressure on the cancer while reducing treatment-related toxicity.
This shift also changes how the chemotherapy works. In addition to targeting rapidly dividing cancer cells, continuous low-dose treatment can inhibit tumor angiogenesis, modulate the tumor microenvironment, and enhance anti-tumor immune responses.
Clinical evidence suggests these biological effects can translate into meaningful patient benefit. In a meta-analysis of more than 1,300 patients with metastatic breast cancer, metronomic chemotherapy achieved a clinical benefit rate exceeding 55%, while maintaining a favorable safety profile. Improved tolerability may also support better treatment adherence and quality of life, particularly for older adults and patients with significant comorbidities.[4]
Another important example of chemotherapy optimization is the development of antibody-drug conjugates (ADCs). Rather than changing the cytotoxic payload itself, ADCs improve how chemotherapy is delivered by linking potent anticancer drugs to monoclonal antibodies that selectively recognize tumor-associated antigens. While approved ADCs have validated this approach clinically, researchers continue to optimize their design (including the antibody, linker, payload, and dosing strategy) to maximize tumor delivery while minimizing toxicity and resistance. [3]
The drugs themselves have not changed; the innovation lies in how they are dosed and deployed.
Making Surgery More Precise
Surgery remains one of the most effective treatments for many solid tumors. Its success depends not only on removing the tumor, but on achieving clear surgical margins while preserving as much healthy tissue as possible.
Advances in surgical technology are improving how these goals are achieved. Robotic-assisted platforms, fluorescence-guided imaging, and artificial intelligence are enabling surgeons to visualize tumors with greater accuracy and make more informed intraoperative decisions.
Fluorescence-guided surgery uses tumor-targeting imaging agents that emit light under near-infrared imaging, helping distinguish malignant tissue from surrounding healthy structures in real time. Artificial intelligence can further support surgical planning and intraoperative decision-making by identifying suspicious tissue and enhancing image interpretation.
Early clinical studies suggest these technologies can improve tumor visualization, increase rates of complete tumor resection, and reduce residual disease, with the potential to decrease repeat surgeries and improve patient outcomes.[5]
The drive toward greater precision is also accelerating the development of non-invasive alternatives. Ultrasound, long used as a diagnostic imaging tool, is now being developed as a therapeutic platform through approaches such as focused ultrasound and histotripsy. By concentrating acoustic energy on defined areas of tissue, these techniques aim to destroy tumors without surgical incisions, illustrating the same principle: the technology is familiar, but its application is more precise and more powerful.
The objective of surgery has not changed. The innovation lies in helping clinicians achieve it with greater precision, and, in some cases, with less invasive approaches.
Personalizing Endocrine Therapy
Endocrine therapy demonstrates how decades of biological understanding can be translated into personalized cancer therapies.
Endocrine therapy has been a cornerstone of treatment for hormone receptor-positive breast cancer for decades. By blocking estrogen signalling or reducing estrogen production, therapies such as tamoxifen and aromatase inhibitors help prevent tumor growth and reduce the risk of recurrence.
Today, the focus is increasingly on optimizing who receives which therapy, and for how long. Clinical evidence suggests that extending endocrine therapy beyond five years can further reduce recurrence risk in selected patients, while ovarian function suppression combined with endocrine therapy provides additional benefit for some postmenopausal women at higher risk of recurrence. In some studies, combining endocrine therapy with ovarian function suppression reduced the risk of invasive breast cancer recurrence by approximately 40%.[6]
The biological target has not changed; the innovation lies in tailoring treatment to the patients most likely to benefit.
Why Optimization Matters
One of the greatest advantages of refining established therapies is that researchers are not starting from scratch.
These treatments are supported by decades of biological understanding, well-characterized safety profiles, and extensive clinical experience. Rather than first having to establish whether a therapeutic principle works, researchers can focus on improving how it works.
This means asking questions such as:
• Can treatment be delivered more precisely?
• Can side effects be reduced?
• Can patient selection be improved?
• Can therapies be combined or sequenced more effectively?
• Can treatment duration be tailored to individual risk?
Answering these questions can accelerate clinical adoption, improve therapeutic performance, and deliver meaningful benefits to patients without reinventing the underlying biology.
The Future May Be Smarter, Not Just Newer
Discovery will always remain essential to advancing cancer care. But innovation extends well beyond discovering new therapies; it also includes finding better ways to use the ones we already have.[7]
As this article illustrates, meaningful advances can also emerge from refining treatments that are already part of clinical practice, improving how they are delivered, dosed, personalized, and applied.
Ultimately, patients do not benefit from novelty for its own sake. They benefit from therapies that are safer, more effective, more precise, and better suited to their individual disease.
At Helix BioPharma, we believe meaningful innovation begins with a strong biological foundation. By building on established science and continuously optimizing how therapies are delivered, combined, and deployed, we aim to develop smarter approaches that address current treatment limitations and bring meaningful benefits closer to patients, faster.
Ref:
1. Taunk NK, Escorcia FE, Lewis JS, Bodei L. Radiopharmaceuticals for Cancer Diagnosis and Therapy: New Targets, New Therapies-Alpha-Emitters, Novel Targets. Cancer J. 2024;30(3):218-223. doi:10.1097/PPO.0000000000000720
2. Radiopharmaceuticals emerging as new cancer therapy. Cancer.gov. October 26, 2020. Accessed June 8, 2026. https://www.cancer.gov/news-events/cancer-currents-blog/2020/radiopharmaceuticals-cancer-radiation-therapy
3. Liu, K., Li, M., Li, Y. et al. A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers. Mol Cancer 23, 62 (2024). https://doi.org/10.1186/s12943-024-01963-7
4. Muthusamy P, Chary KV, Nalini GK. Metronomic Chemotherapy: Seems Prowess to Battle against Cancer in Current Scenario. J Clin Diagn Res. 2016;10(11):FC09-FC13. doi:10.7860/JCDR/2016/23782.8802
5. Advancing Cancer Therapy. Nat Cancer 2, 245–246 (2021). https://doi.org/10.1038/s43018-021-00192-x
6. Hong Kong Journal of radiology. Hkjr.org. Accessed June 8, 2026. https://www.hkjr.org/article/v6n3/advances2
7. Zafar A, Khatoon S, Khan MJ, Abu J, Naeem A. Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy. Discov Oncol. 2025;16(1):607. Published 2025 Apr 24. doi:10.1007/s12672-025-02198-8